ERJ May Podcast: using resting pulmonary artery pressure to predict abnormal exercise haemodynamics
Eur Respir J 2016; 47:E65 | |
Blood eosinophil count: a biomarker of an important treatable trait in patients with airway disease Pavord Ian D., Agusti Alvar Eur Respir J 2016; 47:1299-1303 | |
Is exhaled nitric oxide a marker of air pollution effect? Annesi-Maesano Isabella, Dinh-Xuan Anh Tuan Eur Respir J 2016; 47:1304-1306 | |
Are COPD and cardiovascular disease fundamentally intertwined? Bafadhel Mona, Russell Richard E.K. Eur Respir J 2016; 47:1307-1309 | |
Searching for the happy medium in the therapeutic approach to childhood sleep disordered breathing Campos-Rodriguez Francisco, Martínez-García Miguel A. Eur Respir J 2016; 47:1310-1312 | |
Guided duration of anticoagulation after unprovoked venous thromboembolism using D-dimer testing Couturaud Francis Eur Respir J 2016; 47:1313-1314 | |
Exercise pulmonary haemodynamics: a test in search of purpose Coghlan J. Gerry, Bogaard Ham Jan Eur Respir J 2016; 47:1315-1317 | |
Central pulmonary arteries in idiopathic pulmonary fibrosis: size really matters Price Laura C., Devaraj Anand, Wort S. John Eur Respir J 2016; 47:1318-1320 | |
Targeted treatment of idiopathic pulmonary fibrosis: one step at a time Richeldi Luca Eur Respir J 2016; 47:1321-1323 | |
What's it like to live with idiopathic pulmonary fibrosis? Ask the experts Russell Anne-Marie, Swigris Jeffrey J. Eur Respir J 2016; 47:1324-1326 | |
Advancing global programmatic management of latent tuberculosis infection for at risk populations Getahun Haileyesus, Matteelli Alberto, Abubakar Ibrahim, Hauer Barbara, Pontali Emanuele, Migliori Giovanni Battista Eur Respir J 2016; 47:1327-1330 | |
The 5000% case: a glimpse into the financial issue of lung cancer treatment Remon Jordi, Bonastre Julia, Besse Benjamin Eur Respir J 2016; 47:1331-1333 | |
Toward better management of rare and orphan pulmonary diseases Harari Sergio, Humbert Marc Eur Respir J 2016; 47:1334-1335 | |
Increasing implementation and delivery of pulmonary rehabilitation: key messages from the new ATS/ERS policy statement Vogiatzis Ioannis, Rochester Carolyn L., Spruit Martijn A., Troosters Thierry, Clini Enrico M. Eur Respir J 2016; 47:1336-1341 | |
Clinical trials: registration and transparency Sotgiu Giovanni, Humbert Marc, Dinh-Xuan Anh Tuan, Migliori Giovanni Battista Eur Respir J 2016; 47:1342-1344 | |
Call for urgent actions to ensure access to early diagnosis and care of tuberculosis among refugees: Statement of the European Respiratory Society and the European Region of the International Union Against Tuberculosis and Lung Disease Dara Masoud, Solovic Ivan, Sotgiu Giovanni, D'Ambrosio Lia, Centis Rosella, Goletti Delia, Duarte Raquel, Aliberti Stefano, de Benedictis Fernando Maria, Bothamley Graham, Schaberg Tom, Abubakar Ibrahim, Ward Brian, Teixeira Vitor, Gratziou Christina, Migliori Giovanni Battista Eur Respir J 2016; 47:1345-1347 | |
Traffic-related air pollution and alveolar nitric oxide in southern California children Eckel Sandrah P., Zhang Zilu, Habre Rima, Rappaport Edward B., Linn William S., Berhane Kiros, Zhang Yue, Bastain Theresa M., Gilliland Frank D. Eur Respir J 2016; 47:1348-1356 | |
Inflammatory bowel disease and risk of mortality in COPD Vutcovici Maria, Bitton Alain, Ernst Pierre, Kezouh Abbas, Suissa Samy, Brassard Paul Eur Respir J 2016; 47:1357-1364 | |
Circulating desmosine levels do not predict emphysema progression but are associated with cardiovascular risk and mortality in COPD Rabinovich Roberto A., Miller Bruce E., Wrobel Karolina, Ranjit Kareshma, Williams Michelle C., Drost Ellen, Edwards Lisa D., Lomas David A., Rennard Stephen I., Agustí Alvar, Tal-Singer Ruth, Vestbo Jørgen, Wouters Emiel F.M., John Michelle, van Beek Edwin J.R., Murchison John T, Bolton Charlotte E, MacNee William, Huang Jeffrey T.J. Eur Respir J 2016; 47:1365-1373 | |
Blood eosinophils as a marker of response to inhaled corticosteroids in COPD Barnes Neil C., Sharma Raj, Lettis Sally, Calverley Peter M.A. Eur Respir J 2016; 47:1374-1382 | |
Serum periostin in obstructive airways disease Fingleton James, Braithwaite Irene, Travers Justin, Bowles Darren, Strik Rianne, Siebers Rob, Holweg Cecile, Matthews John, Weatherall Mark, Beasley Richard Eur Respir J 2016; 47:1383-1391 | |
Pseudomonas infection and mucociliary and absorptive clearance in the cystic fibrosis lung Locke Landon W., Myerburg Michael M., Weiner Daniel J., Markovetz Matthew R., Parker Robert S., Muthukrishnan Ashok, Weber Lawrence, Czachowski Michael R., Lacy Ryan T., Pilewski Joseph M., Corcoran Timothy E. Eur Respir J 2016; 47:1392-1401 | |
Natural history of sleep disordered breathing in prepubertal children transitioning to adolescence Bixler Edward O., Fernandez-Mendoza Julio, Liao Duanping, Calhoun Susan, Rodriguez-Colon Sol M., Gaines Jordan, He Fan, Vgontzas Alexandros N. Eur Respir J 2016; 47:1402-1409 | |
Endoscopy evaluation to predict oral appliance outcomes in obstructive sleep apnoea Okuno Kentaro, Sasao Yasuhiro, Nohara Kanji, Sakai Takayoshi, Pliska Benjamin T., Lowe Alan A., Ryan C. Frank, Almeida Fernanda R. Eur Respir J 2016; 47:1410-1419 | |
Modafinil/armodafinil in obstructive sleep apnoea: a systematic review and meta-analysis Chapman Julia L., Vakulin Andrew, Hedner Jan, Yee Brendon J., Marshall Nathaniel S. Eur Respir J 2016; 47:1420-1428 | |
Duration of anticoagulation after isolated pulmonary embolism Palareti Gualtiero, Cosmi Benilde, Antonucci Emilia, Legnani Cristina, Erba Nicoletta, Ghirarduzzi Angelo, Poli Daniela, Testa Sophie, Tosetto Alberto, Pengo Vittorio, Prandoni Paolo Eur Respir J 2016; 47:1429-1435 | |
Resting pulmonary artery pressure of 21–24 mmHg predicts abnormal exercise haemodynamics Lau Edmund M.T., Godinas Laurent, Sitbon Olivier, Montani David, Savale Laurent, Jaïs Xavier, Lador Frederic, Gunther Sven, Celermajer David S., Simonneau Gérald, Humbert Marc, Chemla Denis, Herve Philippe Eur Respir J 2016; 47:1436-1444 | |
Pulmonary artery size as a predictor of outcomes in idiopathic pulmonary fibrosis Shin Stephanie, King Christopher S., Puri Nitin, Shlobin Oksana A., Brown A. Whitney, Ahmad Shahzad, Weir Nargues A., Nathan Steven D. Eur Respir J 2016; 47:1445-1451 | |
Pulmonary rehabilitation in lymphangioleiomyomatosis: a controlled clinical trial Araujo Mariana S., Baldi Bruno G., Freitas Carolina S.G., Albuquerque André L.P., Marques da Silva Cibele C.B., Kairalla Ronaldo A., Carvalho Celso R.F., Carvalho Carlos R.R. Eur Respir J 2016; 47:1452-1460 | |
Predictors of objective cough frequency in pulmonary sarcoidosis Sinha Aish, Lee Kai K., Rafferty Gerrard F., Yousaf Nadia, Pavord Ian D., Galloway James, Birring Surinder S. Eur Respir J 2016; 47:1461-1471 | |
The lived experience with idiopathic pulmonary fibrosis: a qualitative study Overgaard Dorthe, Kaldan Gudrun, Marsaa Kristoffer, Nielsen Thyge Lynghøj, Shaker Saher Burhan, Egerod Ingrid Eur Respir J 2016; 47:1472-1480 | |
FG-3019 anti-connective tissue growth factor monoclonal antibody: results of an open-label clinical trial in idiopathic pulmonary fibrosis Raghu Ganesh, Scholand Mary Beth, de Andrade João, Lancaster Lisa, Mageto Yolanda, Goldin Jonathan, Brown Kevin K., Flaherty Kevin R., Wencel Mark, Wanger Jack, Neff Thomas, Valone Frank, Stauffer John, Porter Seth Eur Respir J 2016; 47:1481-1491 | |
Monitoring latent tuberculosis infection diagnosis and management in the Netherlands Erkens Connie G.M., Slump Erika, Verhagen Maurits, Schimmel Henrieke, de Vries Gerard, Cobelens Frank, van den Hof Susan Eur Respir J 2016; 47:1492-1501 | |
Inequalities in lung cancer: a world of EGFR Carbonnaux Mélodie, Souquet Pierre-Jean, Meert Anne-Pascale, Scherpereel Arnaud, Peters Matthew, Couraud Sébastien Eur Respir J 2016; 47:1502-1509 | |
Outcome of incidentally detected airway nodules Kim Hyung-Jun, Kim Deog Kyeom, Kim Young Whan, Lee Yeon Joo, Park Jong Sun, Cho Young-Jae, Kim Se Joong, Yoon Ho Il, Lee Jae Ho, Lee Choon-Taek Eur Respir J 2016; 47:1510-1517 | |
Pulmonary veno-occlusive disease Montani David, Lau Edmund M., Dorfmüller Peter, Girerd Barbara, Jaïs Xavier, Savale Laurent, Perros Frederic, Nossent Esther, Garcia Gilles, Parent Florence, Fadel Elie, Soubrier Florent, Sitbon Olivier, Simonneau Gérald, Humbert Marc Eur Respir J 2016; 47:1518-1534 | |
Connective tissue diseases, multimorbidity and the ageing lung Spagnolo Paolo, Cordier Jean-François, Cottin Vincent Eur Respir J 2016; 47:1535-1558 | |
A comparison of COPD patients with and without ACOS in the ECLIPSE study Wurst Keele E., Rheault Tara R., Edwards Lisa, Tal-Singer Ruth, Agusti Alvar, Vestbo Jørgen Eur Respir J 2016; 47:1559-1562 | |
Blood eosinophil count to predict bronchial eosinophilic inflammation in COPD Schleich Florence, Corhay Jean-Louis, Louis Renaud Eur Respir J 2016; 47:1562-1564 | |
Can health status questionnaires be used as a measure of physical activity in COPD patients? Demeyer Heleen, Dueñas-Espín Ivan, De Jongh Corina, Louvaris Zafeiris, Hornikx Miek, Gimeno-Santos Elena, Loeckx Matthias, Vogiatzis Ioannis, Janssens Wim, Hopkinson Nicholas S., Rabinovich Roberto A., Karlsson Niklas, Garcia-Aymerich Judith, Troosters Thierry Eur Respir J 2016; 47:1565-1568 | |
Urokinase plasminogen activator receptor polymorphisms and airway remodelling in asthma Ierodiakonou Despo, Portelli Michael A., Postma Dirkje S., Koppelman Gerard H., Gerritsen Jorrit, ten Hacken Nick H.T., Timens Wim, Boezen H. Marike, Vonk Judith M., Sayers Ian Eur Respir J 2016; 47:1568-1571 | |
3-day mortality in hospitalised community-acquired pneumonia: frequency and risk factors Kolditz Martin, Bauer Torsten T., König Thomas, Rohde Gernot, Ewig Santiago Eur Respir J 2016; 47:1572-1574 | |
Should all adult cystic fibrosis patients with repeated nontuberculous mycobacteria cultures receive specific treatment? A 10-year case–control study Albrecht Christiane, Ringshausen Felix, Ott Sebastian, Wagner Dirk, Rademacher Jessica, Schneider Michael, Welte Tobias, Pletz Mathias W. Eur Respir J 2016; 47:1575-1577 | |
High levels of neurological involvement but low mortality in miliary tuberculosis: a 6-year case-series from the UK Venkatraman Navin, King Thomas, Bell David, Woltmann Gerrit, Wiselka Martin, Abubakar Ibrahim, Pareek Manish Eur Respir J 2016; 47:1578-1581 | |
First experience of effectiveness and safety of bedaquiline for 18 months within an optimised regimen for XDR-TB Lewis Joseph M., Hine Paul, Walker Jenny, Khoo Saye H., Taegtmeyer Miriam, Squire S. Bertel, Sloan Derek J. Eur Respir J 2016; 47:1581-1584 | |
An overview on tuberculosis-specific hospitals in China in 2009: results of a national survey Pang Yu, Du Jian, Qin Zhi Zhen, Greenwald Zoë, Liu Yuhong, Mi Fengling, Zhao Yanlin, Li Liang Eur Respir J 2016; 47:1584-1587 | |
First independent evaluation of QuantiFERON-TB Plus performance Barcellini Lucia, Borroni Emanuele, Brown James, Brunetti Enrico, Codecasa Luigi, Cugnata Federica, Dal Monte Paola, Di Serio Clelia, Goletti Delia, Lombardi Giulia, Lipman Marc, Rancoita Paola M.V., Tadolini Marina, Cirillo Daniela M. Eur Respir J 2016; 47:1587-1590 | |
Efficacy, safety and tolerability of linezolid for the treatment of XDR-TB: a study in China Berry Catherine, Yates Tom A., Seddon James A., Phillips Patrick P. J., du Cros Philipp Eur Respir J 2016; 47:1591-1592 | |
Benefit of treatment of latent tuberculosis infection in individual patients Fluegge Kyle Eur Respir J 2016; 47:1592-1594 | |
Benefit of treatment of latent tuberculosis infection in individual patients Dobler Claudia C., Martin Andrew, Marks Guy B. Eur Respir J 2016; 47:1594-1595 | |